BioSenic S.A. Reports Transparency Notification from ABO Infinium
![BioSenic S.A. Reports Transparency Notification from ABO Infinium](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Transparency Notification Received from ABO Infinium Americas OpCo LTD
REGULATED INFORMATION
Article 14 of the Law of 2 May 2007 on Disclosure of Major Holdings
Mont-Saint-Guibert, Belgium - BioSenic S.A. (Euronext Brussels and Paris: BIOS), a clinical-stage company focused on severe autoimmune and inflammatory diseases and cell therapy, has announced the receipt of a transparency notification from ABO Infinium Americas OpCo LTD. The details regarding this notification are provided below, and the full text can be found on the BioSenic website under "Major shareholders & transparency notices."
The notification indicates that the voting rights associated with BioSenic's shares held by ABO Infinium Americas OpCo LTD have fallen below the 5% threshold due to the transfer of shares of BioSenic.
The details contained in the notification from ABO Infinium Americas OpCo LTD, dated August 16, 2024, include the following:
- Reason for Notification: Acquisition or transfer of voting securities or voting rights
- Notification By: A parent company or controlling person
- Person Subject to the Notification Requirement:
- ABO Infinium Americas OpCo LTD
- ABO Securities
- Omega Financial Corporation
- Mr. Pierre Vannineuse
- Transaction Date: August 14, 2024
- Threshold Crossed: 5%
- Denominator: 251,312,817
- Full Chain of Controlled Undertakings: ABO Infinium Americas OpCo LTD (303 Shriley Street, Nassau, Bahamas) is wholly owned by ABO Securities (71 Fort Street, Georges Town, Grand Cayman, Cayman Islands). ABO Securities is entirely controlled by Omega Financial Corporation (71 Fort Street, Georges Town, Grand Cayman, Cayman Islands), which in turn is fully owned by Pierre Vannineuse.
About BioSenic
BioSenic is a premier biotech entity focused on creating clinical assets derived from its Medsenic’s arsenic trioxide (ATO) platform. The primary target indications within its autoimmune platform comprise graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), and now systemic sclerosis (SSc).
Following a merger in October 2022, BioSenic unified the strategic advantages of Medsenic and Bone Therapeutics. This merger empowers Medsenic/BioSenic to explore a new range of anti-inflammatory and anti-autoimmune formulations leveraging the immunomodulatory properties of ATO and oral ATO (OATO).
BioSenic is located in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. More details about BioSenic can be found at http://www.biosenic.com.
About the Main Medsenic/BioSenic Technology Platform
The ATO platform produces active products with immunomodulatory capabilities and effects on activated immune cells. A notable application is its utilization in onco-immunology for treating chronic graft-versus-host disease (cGvHD), which presents significant challenges for long-term survival following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Medsenic has successfully completed a phase 2 trial with its intravenous formulation, Arscimed, which has received orphan drug designation from FDA and EMA. The company is preparing for an international phase 3 confirmatory study with its new OATO formulation. Additionally, the platform targets moderate-to-severe systemic lupus erythematosus (SLE) by employing the same OATO formulation, which has demonstrated safety and efficacy across multiple affected organs. Systemic sclerosis is now integrated into the clinical pipeline of Medsenic/BioSenic. This serious chronic condition impacts the skin, lungs, and vascularization and currently lacks effective treatments. Positive preclinical studies on relevant animal models support the development of a phase 2 clinical protocol using innovative immunomodulatory formulations of recognized APIs that activate the immune system.
The company is prioritizing its R&D and clinical initiatives towards a focused, expedited growth of its autoimmune platform.
Furthermore, BioSenic is exploring a renewed interest in its allogeneic cell therapy platform originating from Bone Therapeutics, using differentiated bone marrow Mesenchymal Stromal Cells (MSCs) to isolate and refine biological subcellular components. These cells may lead to new vesicles with a unique approach to organ repair. BioSenic is currently engaged in identifying new patentable methodologies in this complex therapeutic area.
For Further Information, Please Contact:
BioSenic SA
François Rieger, PhD, CEO
Tel: +33 (0)671 73 31 59
investorrelations@biosenic.com
Frequently Asked Questions
1. What is the significance of the transparency notification received by BioSenic?
The transparency notification signifies that the voting rights associated with BioSenic's shares held by ABO Infinium Americas OpCo LTD have decreased below the 5% threshold due to share transfers.
2. What can you tell me about BioSenic's focus areas?
BioSenic specializes in developing clinical assets primarily targeting serious autoimmune diseases and inflammatory conditions, specifically GvHD, SLE, and systemic sclerosis.
3. Where is BioSenic headquartered?
BioSenic is based in the Louvain-la-Neuve Science Park located in Mont-Saint-Guibert, Belgium.
4. What is the purpose of the ATO platform developed by BioSenic?
The ATO platform is designed to produce active products with immunomodulatory properties, particularly aimed at treating conditions like chronic graft-versus-host disease.
5. How is BioSenic addressing its allogeneic cell therapy platform?
BioSenic is exploring its allogeneic cell therapy platform by focusing on differentiated bone marrow MSCs to isolate and develop biological components that could facilitate organ repair.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/